LivaNova PLC (NASDAQ:LIVN) Shares Sold by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP lowered its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 19.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 520,623 shares of the company's stock after selling 122,412 shares during the quarter. ExodusPoint Capital Management LP owned approximately 0.96% of LivaNova worth $24,110,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in LivaNova by 12.7% in the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after purchasing an additional 265,291 shares during the last quarter. Point72 Asset Management L.P. increased its stake in shares of LivaNova by 62.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock valued at $109,914,000 after acquiring an additional 806,374 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of LivaNova by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock worth $70,676,000 after acquiring an additional 8,331 shares during the period. Emerald Advisers LLC boosted its position in shares of LivaNova by 8.2% in the fourth quarter. Emerald Advisers LLC now owns 752,540 shares of the company's stock worth $34,850,000 after acquiring an additional 57,035 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in LivaNova by 17.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company's stock valued at $32,678,000 after purchasing an additional 93,311 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LIVN has been the topic of a number of research analyst reports. Mizuho decreased their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a report on Monday, March 17th. StockNews.com upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, March 25th. Barclays dropped their target price on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a research report on Friday, March 7th. Finally, Stifel Nicolaus reduced their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $61.17.

LivaNova Stock Down 1.9 %

NASDAQ LIVN traded down $0.66 during trading hours on Tuesday, reaching $34.74. 266,878 shares of the company traded hands, compared to its average volume of 616,609. The stock has a market capitalization of $1.89 billion, a PE ratio of 82.78 and a beta of 0.90. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 12 month low of $34.03 and a 12 month high of $64.48. The company has a 50 day moving average of $43.19 and a two-hundred day moving average of $47.97.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.